The Changing Landscape of Anticoagulant Therapy – ISTH
International Society on Thrombosis and Haemostasis shared a post on LinkedIn about a recent article by Surasak Wichaiyo, published in JTH, adding:
“From heparin and warfarin to DOACs and emerging factor XI and XII inhibitors, the pharmacology of anticoagulation continues to evolve.
A new review in the Journal of Thrombosis and Haemostasis (JTH) examines the mechanisms, clinical applications and limitations of currently available anticoagulants while looking ahead to novel target-specific approaches.
The review explores how direct oral anticoagulants have reshaped the prevention and treatment of thromboembolic disease and why FXI and FXII have emerged as promising targets in the search for effective anticoagulation with potentially lower bleeding risk.”
Title: Pharmacology of anticoagulants: from heparin to novel target-specific agents
Authors: Surasak Wichaiyo
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 28, 2026, 14:56Elizabeth Shirley: COVID-19 Vaccines, Spike Protein and Nitric Oxide Bioavailability
-
Oct 28, 2026, 14:39David Ledger: Anticoagulation Advances as Factor XIa Inhibition Reaches a New Milestone
-
Oct 28, 2026, 14:37Advancing Liver Health in Haemophilia Care – EAHAD
-
Oct 28, 2026, 14:17Clusterin Regulates von Willebrand Factor Multimer Stability Through ADAMTS13 Inhibition
-
Oct 28, 2026, 14:14Mina Jarrahi: Platelet-Rich Fibrin for Periodontal Regeneration
-
Oct 28, 2026, 14:06Mohammed Alo: A Stent Treats the Blockage, Not the Underlying Disease
-
Oct 28, 2026, 13:58Vladimir Lemaire: When Blood Clots Affect Elite Athletes
-
Oct 28, 2026, 13:27M. Alejandro Mosso-Pani: Dengue in Florida – Why Platelet Function Matters
-
Oct 28, 2026, 13:13Michael Cahillane: Three-Buffy-Coat Platelets – Strengthening Blood Supply Resilience